User profiles for J. Goh

Jin X. Goh

- Verified email at colby.edu - Cited by 11635

Jeffrey C Goh

- Verified email at health.qld.gov.au - Cited by 7085

Joel Goh

- Verified email at nus.edu.sg - Cited by 3800

Mini meta‐analysis of your own studies: Some arguments on why and a primer on how

JX Goh, JA Hall, R Rosenthal - Social and Personality …, 2016 - Wiley Online Library
Goh is a doctoral student in social psychology and personality at Northeastern University.
His research focuses on the relationship between prejudice and nonverbal behavior. He is …

Recent Advances in Alkenyl sp2 C–H and C–F Bond Functionalizations: Scope, Mechanism, and Applications

MZ Lu, J Goh, M Maraswami, Z Jia, JS Tian… - Chemical …, 2022 - ACS Publications
Alkenes and their derivatives are featured widely in a variety of natural products, pharmaceuticals,
and advanced materials. Significant efforts have been made toward the development …

Estimating the attributable cost of physician burnout in the United States

…, LN Dyrbye, LC Fiscus, M Trockel, J Goh - Annals of internal …, 2019 - acpjournals.org
… Shanafelt T , Goh J , Sinsky C . The business case for investing in physician well-being. …
Goh received a startup grant (R-314-000-110-133) from the National University of Singapore…

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …

…, JC Goh, DM O'Malley, DK Armstrong, J Garcia-Donas… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…

[HTML][HTML] Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma

…, AY Shah, C Suárez, A Hamzaj, JC Goh… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …

[HTML][HTML] Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

…, E Winquist, P Maroto, JC Goh… - … England Journal of …, 2021 - Mass Medical Soc
Background Lenvatinib in combination with pembrolizumab or everolimus has activity against
advanced renal cell carcinoma. The efficacy of these regimens as compared with that of …

Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors

…, ET Courtois, D Sengupta, Y Tan, KH Chen, JJL Goh… - Nature …, 2017 - nature.com
Intratumoral heterogeneity is a major obstacle to cancer treatment and a significant
confounding factor in bulk-tumor profiling. We performed an unbiased analysis of transcriptional …

Disruptive technology: How Kodak missed the digital photography revolution

HC Lucas Jr, JM Goh - The Journal of Strategic Information Systems, 2009 - Elsevier
The purpose of this paper is to analyze how a firm responds to a challenge from a transformational
technology that poses a threat to its historical business model. We extend Christensen…

MAD-GAN: Multivariate anomaly detection for time series data with generative adversarial networks

D Li, D Chen, B Jin, L Shi, J Goh, SK Ng - International conference on …, 2019 - Springer
… The residual at time t for the \(j-th\) test sample is calculated as $$\begin{aligned} Res(X^{tes}_{j,t})=\sum
_{i=1}^T \mid x_{j,t}^{tes,i}-G_{rnn}(Z^{k,i}_{j,t}) \mid \end{aligned}$$ …

Is a bond rating downgrade bad news, good news, or no news for stockholders?

JC Goh, LH Ederington - The journal of finance, 1993 - Wiley Online Library
We examine the reaction of common stock returns to bond rating changes. While recent
studies find a significant negative stock response to downgrades, we argue that this reaction …